Table 2.
Retention rates as of December 2020 and reasons for discontinuation for patients inducted on buprenorphine-naloxone therapy (n = 277)
| Number (%) | |
|---|---|
| Overall | 277 |
| Continued treatment as of December 2020 | 190 (68.6) |
| 90-day retention | 223 (84.5) |
| 180-day retention | 192 (79.0) |
| In-person inductees | 166 |
| 90-day retention | 156 (93.9) |
| 180-day retention | 151 (91.5) |
| 365-day retention | 110 (79.1) |
| Telehealth inductees | 111 |
| 90-day retention | 67 (68.4) |
| 180-day retention | 40 (51.9) |
| Overall discontinued patients | 87 (31.4) |
| Reason unknown | 53 (19.1) |
| Transferred MAT care elsewhere | 23 (8.3) |
| Deceased | 5 (1.8) |